Calls for collaboration
Survey: ways to mitigate and address patient trust within the complex IVF journey
Dear Colleagues and Fertility Healthcare Professionals,
My name is Kyona Chambre, and I am currently completing my Master’s thesis at the University of Siena, Italy. I am seeking the expertise of Certified Genetic Counselors, GC Students, and IVF healthcare professionals for a brief study on the integration of genetic counseling within the IVF pathway.
Research Mission: The core objective of this study is to identify ways to mitigate and address patient trust within the complex IVF journey. By capturing the most current, up-to-date perspectives from both veteran practitioners and students working toward accreditation, this research aims to:
- Strengthen informed decision-making for patients.
- Protect and encourage patient autonomy in reproductive choices.
- Evaluate if current genetic counseling integration is viewed as beneficial to healthcare professionals within Western clinical and ethical frameworks (Europe and North America).
Participation Details:
- Time: No longer than 10 minutes.
- Deadline: Please submit your responses until March 25, 2026.
- Privacy: All responses are strictly anonymous.
- Data Usage: Collected data will be used exclusively for this Master’s thesis and no other purpose.
Survey Link:
A Request for Outreach: To ensure a broad spectrum of perspectives, please forward this email to any English or French-speaking colleagues in your network who work in prenatal, preconception, or IVF settings.
Thank you for your expertise and for helping to improve the patient experience in reproductive medicine.
Sincerely,
Kyona Chambre, Master’s Candidate, Genetic Counseling
Survey: Pharmacogenetics (PGx) Readiness in Healthcare Systems
This survey is part of a MSc thesis conducted at Maastricht University, The Netherlands, in collaboration with iGene Pharmaco. The research aims to assess how ready different healthcare systems are for the implementation of pharmacogenetics (PGx) in routine clinical care.
The study seeks to better understand key factors influencing PGx adoption, including regulatory frameworks, reimbursement structures, professional training, patient awareness, laboratory capacity, and IT integration.
Healthcare professionals, researchers, laboratory specialists, and policymakers with experience or interest in pharmacogenetics or precision medicine are invited to share their perspectives. The insights collected will contribute to a broader understanding of how pharmacogenetics can be integrated more effectively into everyday healthcare practice.
The survey takes approximately 2–3 minutes to complete and is anonymous, unless participants choose to share their contact details for potential follow-up research.
Survey link: https://maastrichtuniversity.eu.qualtrics.com/jfe/form/SV_8uKOCPRqUlYNoDI
The survey will remain open until 1-6-2026
canSERV - Invitation to join the European Network for Personalized Oncology and its European Molecular Tumor Board Network
A european-wide initiative by the EU cluster project canSERV
We would like to invite anyone involved in a Molecular Tumor Board (MTB) – e.g., physicians, scientists, patient representatives, ethicists – to join the European Network for Personalised Oncology (ENPO) and its European Molecular Tumor Board Network (EMTBN), both being established through the EU cluster project canSERV (visit canSERV About). The European Network for Personalised Oncology (ENPO) aims to provide state-of-the-art guidance and support to accelerate the implementation of personalised oncology. Through canSERV, the ENPO will establish the European Molecular Tumor Board Network (EMTBN), which aims to guide the establishment of MTB Standard Operating Procedures (consensus standards) and the set-up of a public registry of MTB recommendation outcomes. The ENPO and EMTBN will not be limited to the canSERV consortium partners but open to the wider community to be as inclusive and engaging as possible. Although participation in the networks is on a voluntary basis, some specific activities can be considered for cost reimbursement for those who will actively contribute.
canSERV - Call for Service Provision on ”Advancing Personalised Oncology"
The canSERV Consortium announces its first Challenge-Call on
“Advancing Personalised Oncology”.
Cancer Researchers in, and outside the EU are invited to apply for free access to cutting-edge transnational services with an indicative overall budget of EUR 500,000. The aim of this call is to accelerate knowledge gain in personalised oncology with specific emphasis on multi-level data-based treatment guidance linked to Molecular Tumour Boards1.
The projects supported under this call will support the advancement and implementation of personalized medicine strategies for all cancer patients in Europe, contributing to the overarching goals of the Cancer Mission Board.
IGPrare Project - Partnership between Aix-Marseille University and EURODIS
This research project, elaborated in collaboration with Eurordis (https://www.eurordis.org/), aims to study the genetic information disclosure to a patient's family in case of a diagnosis of rare genetic disease, and to propose solutions to improve the efficiency and acceptability of this procedure in the future.
This European scale study aims to identify and review the different legal framework and ethical recommendations elaborated in European countries to disclose genetic information to family members.
You can find further information here.
If you are a geneticist or genetic counsellor please and you would like to take part, Please complete the questionnaire (https://columbo.univ-amu.fr/index.php/589445?lang=en). It should take about 10 minutes. Your input would be very much appreciated.
Please contact Marion Gottrau if you have any questions.
